Funding for this research was provided by:
National Institute on Aging (NIA R01AG046171)
National Institutes of Health (RF1AG051550, RF1AG057452, R01AG059093, RF1AG058942, U01AG061359, U19AG063744)
Foundation for the National Institutes of Health (DAOU16AMPA)
Alzheimer's Disease Research Center, Emory University (P30 AG066511)
Emory University (R01 AG070937)
Agricultural Research Service (2032-51530-022-00D, 2032-51530-025-00D)
Received: 10 March 2021
Accepted: 25 August 2021
First Online: 6 September 2021
: All participants from whom plasma and CSF samples were collected provided informed consent under protocols approved by the Institutional Review Board at Emory University. Cohorts included the Emory Healthy Brain Study (IRB00080300), Cognitive Neurology Research (IRB00078273), and Memory @ Emory (IRB00079069). All protocols were reviewed and approved by the Emory University Institutional Review Board. Ethics approval for metabolomics analysis: Analysis samples shipped from Emory were approved for metabolomic profiling and data analysis by the Institutional Review Board at Duke University (Pro00079616).
: Not applicable.
: The authors declare that they have no competing interests. Dr. Kaddurah-Daouk is an inventor on several patents in the field of metabolomics and holds equity in Metabolon Inc. which was not involved in this study.